Vlad Coric has bought stock on 4 days since Oct 2022

Vlad Coric, M.D. is the Chairman and Chief Executive Officer of Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on developing therapies for neurological and neuropsychiatric diseases.( With over 20 years of experience in drug discovery and clinical development at Yale School of Medicine and Bristol-Myers Squibb, Dr. Coric has led Biohaven since its early days as a startup, growing it from a $6 million pre-money valuation to a publicly traded company, culminating in its $13 billion acquisition of the CGRP portfolio by Pfizer in 2022.( Under his leadership, Biohaven achieved FDA approval and global launch of Nurtec ODT (rimegepant) for migraine treatment and filed an NDA for zavegepant, while expanding into international markets and pioneering digital-centric operations.(

Dr. Coric, whose father was a psychiatrist and mother a pharmacist, earned a Bachelor of Science in human physiology from the University of Connecticut and maintains an MD, serving as Associate Clinical Professor of Psychiatry at Yale.( His career highlights include involvement in multiple drug programs across neuroscience, virology, oncology, and immuno-oncology, earning awards such as the Ernst & Young Entrepreneur of the Year 2018 in New York and Top 25 Healthcare Technology Leaders of Connecticut for 2022.( As a recent corporate insider trader at Biohaven, Dr. Coric continues to drive innovation in treatments for conditions like epilepsy, OCD, and spinocerebellar ataxia.(

Written by Perplexity from public sources.